CAR T enters a new era of in vivo reprogramming of T cells Vyriad's Luke Russell explores the technical and economic promise of in vivo CAR T-cell therapies.

The CAR T field is shifting to in vivo platforms that aim to make powerful cell therapies simpler, cheaper, and more accessible. Insights from Vyriad's Luke Russell. #CARTcell #immunotherapy #invivo #biotech #Vyriad #oncology #celltherpay

CAR T enters a new era of in vivo reprogramming of T cells Vyriad's Luke Russell explores the technical and economic promise of in vivo CAR T-cell therapies.

The CAR T field is shifting to in vivo platforms that aim to make powerful cell therapies simpler, cheaper, and more accessible. Insights from Vyriad's Luke Russell. #CARTcell #immunotherapy #invivo #biotech #Vyriad #oncology #celltherpay

✨ La thérapie in vivo #CAR_T 🧬 #VV169 de #Vyriad atteint une élimination tumorale de 100 % dans des études précliniques sur plusieurs #MyélomeMultiples🩸
rarecancernews.com/news/vyriad-...